(MedPage Today) — CHICAGO — Patients with extensive-stage small-cell lung cancer (SCLC) lived significantly longer with the addition of cytotoxic agent lurbinectedin (Zepzelca) to maintenance immunotherapy, a large randomized trial showed…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115728
Author :
Publish date : 2025-05-22 21:00:00
Copyright for syndicated content belongs to the linked Source.
